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R-Bendamustine is an effective treatment for follicular lymphoma (FL). Previous large
trials demonstrated the prognostic role of the molecular minimal residual disease (MRD)
during the most frequently adopted chemotherapeutic regimens, but there are not yet
conclusive data about the effect of combination of rituximab (R) and bendamustine
in terms of MRD clearance. Thus, the aim of this retrospective study was to assess
if and in what extent the combination of rituximab and bendamustine would exert a
significant reduction of the molecular disease in 48 previously untreated FL patients.
The molecular marker at baseline was found in the 62.5% of cases; no significant
differences were observed between patients with or without the molecular marker
in respect of the main clinical features. Moreover, the quantization of the baseline
molecular tumor burden showed a great variability: the median value was 1.4 × 10−2
copies, ranging from 3 × 10−5 to 4 × 104. The initial molecular tumor burden did
not correlate with clinical features and did not impact on the subsequent quality of
response. After treatment, 93% of cases became MRD-negative; the median reduction
of the BCL2/JH load was 4 logs. The 2-years PFS was 85%; it was significantly longer
for patients in complete than for those in partial response (91 vs. 57%; p = 0.002),
and for cases with lower FLIPI-2 score (88 vs. 60%; p = 0.004). On the contrary,
PFS did not differ between patients with or without the molecular marker at baseline;
a molecular tumor burden 15 times higher was observed in the relapsed subgroup
in comparison to the relapse-free one, but this difference did not change the PFS
length. The 2-years OS was 93.6%; the only variable that significantly impacted on
it was the FLIPI-2 score; the presence of the molecular marker at baseline or its
behavior after treatment did not impact on survival. This study, even if retrospective
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and conducted on a small series of patients, would represent a proof of concept that
R-bendamustine is able to so efficaciously eradicate MRD that it could be able to by-pass
the prognostic significance of MRD already demonstrated for other chemotherapeutic
regimens in FL.
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INTRODUCTION
The follicular lymphoma (FL) is the second more frequent
histotype of non-Hodgkin’s lymphomas in the Western world,
and represents one of the entities where the minimal residual
disease (MRD) has been more frequently studied. Indeed, the
history of MRD in FL is now 15 years old, starting with the
demonstration that rituximab (R) significantly reduced the
molecular tumor burden when administered after the CHOP
(Cyclophosphamide, Doxorubicin, Vincristine, Prednisone)
regimen: in that setting, patients achieving MRD negativity
showed a significantly longer event-free survival (Rambaldi
et al., 2002). Then, many other works focused on the MRD in
the transplanted patients: cases MRD-negative after autologous
transplantation remained relapse-free and alive in a higher
percentage than those persistently MRD-positive (Galimberti
et al., 2003; Melillo et al., 2005).
Subsequently, when yttrium-ibritumomab tiuxetan as
consolidation was compared to the observation only, it was
evident that radio-immunotherapy was able to rapidly eradicate
MRD in the majority of patients (Goff et al., 2009): after
this treatment 77% of patients became PCR-negative, with a
significant favorable impact on progression-free survival (PFS)
(Ibatici et al., 2014).
In the 2010, van Oers and colleagues demonstrated, in a
series of relapsed patients, that the presence of the BCL2/JH
at diagnosis had a negative impact on the outcome, whereas
the molecular status before rituximab maintenance did not
discriminate patients with worse outcome (van Oers et al., 2010).
More recently, two large studies conducted by the Fondazione
Italiana Linfomi (FIL) showed that after R-CHOP, R-CVP
(cyclophosphamide, vincristine, prednisone), R-FM (fludarabine
and mitoxantrone) and R-FND (fludarabine, mitoxantrone,
dexamethasone) the MRD status significantly conditioned the
PFS; indeed, patients in partial response (PR) but MRD-negative
showed longer PFS than those in complete remission (CR) but
still MRD-positive (Ladetto et al., 2013; Galimberti et al., 2014).
More recently, the appearance in the scenario of the indolent
lymphomas of the new anti-CD20 monoclonal antibody,
obinutuzumab, prompted researchers to evaluate its value also in
the context of the molecular response. In the Gallium trial, where
CHOP, CVP or bendamustine were combined with rituximab or
obinutuzumab, the new antibody resulted more powerful than
Abbreviations: FL, follicular lymphoma; BM, bone marrow; MRD, minimal
residual disease; R, rituximab; PCR, polymerase chain reaction; PFS, progression-
free survival; OS, overall survival; FIL, fondazione italiana linfomi; CR, complete
remission; PR, partial remission; PET, positron-emission tomography; ESMO,
European Society for Medical Oncology; ROC, receiving operating characteristics;
FLIPI, follicular lymphoma international prognostic index.
rituximab, offering 92.5% of MRD-negativity when combined
with bendamustine, 91.3% with CHOP, and 91.4% with CVP.
Interestingly, the use of obinutuzumab in respect of rituximab
added 13.5% of good molecular responses in the cohort receiving
CHOP, 15.4% in those patients treated with CVP, but only 3% in
the bendamustine arm, thus suggesting that molecular clearance
offered by bendamustine was higher than that induced by the
other two chemotherapeutic regimens (Pott et al., 2016).
Then, MRD is still today a hot topic and often more frequently
it is introduced as aim in several phase-3 trials, as in the
FIL FOLL12 study (trial.gov identifier number: NCT02063685),
where the experimental arm is based on the PET and MRD
results: a de-intensified treatment was reserved to MRD- and
PET-negative cases, a consolidation with radio-immunotherapy
to patients still PET-positive after induction or a pre-emptive
therapy was adopted for PET-negative but MRD-positive cases.
Nevertheless, MRD is still not a decisional tool in the routine
clinical practice: indeed, the ESMO guidelines recently edited,
even if clearly recognizing the prognostic role of the MRD,
state that the MRD “still cannot lead the therapeutic strategy”
(Dreyling et al., 2017).
In this context, few data about R-bendamustine and MRD in
FL are today available: Zohren and colleagues reported that 89.5%
of cases receiving R-bendamustine achieved the MRD negativity,
with a significant advantage in terms of PFS (Zohren et al., 2015).
More recently, in the context of Gadolin trial, obinutuzumab
combined with bendamustine induced 82% of MRD negativity
vs. 43% of the bendamustine alone, with a significant longer PFS
for MRD-negative cases (Pott et al., 2015).
With these premises, we decided to assess the impact of the
R-bendamustine on MRD in a cohort of 48 FL patients treated
in 4 different Italian centers. The aim of this retrospective study
was to measure both by qualitative and quantitative PCR the
molecular tumor burden before and 2 months after the end of
treatment with R-bendamustine. The presence and quantization
of the BCL2/JH rearrangement at baseline and its behavior after
induction was then compared with clinical features, response
rates, and 2-years survivals.
PATIENTS AND METHODS
Patients
This retrospective observational study was conducted in 4 Italian
centers (Pisa, Firenze, Perugia, and Piacenza), in the context of
the routine clinical practice.
Patients with newly diagnosed FL received bendamustine 90
mg/m2, days 1 and 2, once a month, plus rituximab 375 mg/m2,
for total 6 cycles.
All patients signed a consent for leaving the leftover of
samples used for routine molecular analyses for further scientific
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purposes. Forty-eight patients affected by FL were enrolled into
the study on the basis of the residual DNA availability; the
BCL2/JH rearrangement was evaluated on samples harvested at
diagnosis and 8–10 weeks after the end of induction.
Samples have been collected between January 2012 and
December 2015.
In addition to the physical examination and imaging
(total body computed tomography scan, ultrasonography
or x-ray, according to physicians’ decision), at diagnosis
all patients underwent bone marrow (BM) biopsy and
aspirate. In each center, BM biopsies were evaluated also
by immunohistochemistry (at least CD20, CD10, CD5, kappa,
and lambda clonality), in order to confirm the morphological
diagnosis of FL.
Imaging was performed again for assessment of response at
treatment completion in addition to physical examination and
laboratory tests. Quality of response was defined according to the
standardized international criteria (Cheson et al., 2016).
Molecular Assays
Qualitative BCL2/IGH rearrangement analysis was performed
at baseline and at the end of treatment. All qualitative and
quantitative analyses were centralized at themolecular laboratory
of the Hematology of the Pisa University, Italy.
DNA was extracted from BM mononuclear cells by Wizard
Genomic DNA purification kit (Promega Madison WI, USA),
according to the suggestions by the FIL MRD Network (Mannu
et al., 2015). In order to amplify BCL2/IGH rearrangement,
nested PCR reactions were performed as previously described,
both for the MBR and mcr breakpoints (Galimberti et al., 2014).
The sensitivity of the PCR assays was confirmed by testing
serial dilutions of DNA derived from the BCL2/IGH-positive
DOHH-2 cell line, achieving a limiting dilution of 1:10−5, either
for qualitative or quantitative tests.
Statistical Analysis
All statistical analyses were performed using the SPSS 21.0
software (SPSS Inc., Chicago, IL, USA). OS was calculated from
the date of diagnosis to death or last follow-up; PFS wasmeasured
from the date of response to the induction treatment to the
last follow-up, disease progression or relapse. Survival curves
were calculated using the Kaplan-Meier method, and statistical
comparisons between curves were made using the log-rank test.
Post-hoc comparisons were obtained using the Cox proportional
hazard regression method. The Chi squared test, Fisher’s exact
test and Kruskal-Wallis test were used to compare variables when
appropriate. For establishing a possible value of quantitative
BCL2/IGH rearrangement on relapse, a ROC curve was also
performed. All statistical comparisons were two-sided. The date
of the last molecular follow-up was October 2016.
RESULTS
Baseline: Patients Characteristics and
Molecular Marker
Characteristics of the 48 patients enclosed into the study are
reported in the Table 1.
TABLE 1 | Clinical characteristics of the enrolled patients.
Characteristics Number (%)
Number of patients 48
Median age, years 63
range 36-83
SEX
Male 24 (50%)
Female 24 (50%)
HISTOTYPE
Grade 1 17 (35%)
Grade 2 24 (50%)
Grade 3 7 (15%)
ANN ARBOR STAGE
II 8 (16%)
III 20 (42%)
IV 20 (42%)
ECOCG Performance Status >1 4 (8%)
FLIPI2
Low 9 (19%)
Intermediate 31 (65%)
High 8 (16%)
BM involvement 20 (42%)
Their median age was 63 years (range 36–83), and half of them
were male.
By microscope observation, BM resulted infiltrated in 20
cases; the 85% of them were scored as showing a grade 1 or
2 FL; 16% of our patients were in stage II, 42% in stage IV,
and more than 60% presented with intermediate FLIPI-2 risk
score.
By qualitative PCR, BCL2/JH rearrangement at baseline was
found in 30 patients (62.5%). The breakpoint was MBR in 28
cases, and mcr in the remaining two.
In 3 out of the 20 cases withmicroscopic BM infiltration (15%)
we did not find the BCL2/IGH rearrangement, probably for the
presence of some rare breakpoints in the BCL2 gene (not assessed
in this study). On the other hand, in 9 of the 28 cases without BM
infiltration (32%), the molecular marker was found, possibly due
to a submicroscopic involvement.
In this study, the translocation between chromosome 14 and
18 (characteristic of FL) was not assessed.
At baseline, the molecular tumor burden was also assessed
by quantitative PCR (QT-PCR) in the 28 cases with the MBR
breakpoint; it was quantified in 27 of them, because in one case
the BCL2/JH rearrangement resulted at the lowest limit of the test
sensitivity, and thus positive but not quantifiable. As expected,
measures showed a wide inter-patients variability: the median
value was 14 × 10−2 copies, but it ranged from 3 × 10−5 to 4
× 104 copies.
No significant differences were observed for the main
clinical features (age, sex, BM, infiltration, stage, histological
grade, FLIPI-2 score) between patients with or without
molecular marker detected by qualitative or quantitative PCR
(Table 2).
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TABLE 2 | Comparison of the patients’ clinical characteristics according to the
presence/absence of the molecular marker at baseline.
Characteristics Patients with
molecular marker
number (%)
Patients without
molecular marker
number (%)
p
Number of patients 30 18
Median age, years 61 64
range 40-83 36-79 n.s.
SEX
Male 16 (53%) 8 (45%)
Female 14 (47%) 10 (55%) n.s.
HISTOTYPE
Grade 1 11 (37%) 6 (33%) n.s.
Grade 2 15 (50%) 9 (50%)
Grade 3 4 (13%) 3 (17%)
ANN ARBOR STAGE
II 5 (17%) 3 (17%) n.s.
III 12 (40%) 8 (44%)
IV 13 (43%) 7 (39%)
ECOCG Performance Status >1 3 (10%) 1 (6%) n.s.
FLIPI2
Low 6 (20%) 3 (17%) n.s.
Intermediate 19 (63%) 12 (67%)
High 5 (17%) 3 (17%)
BM involvement 12 (40%) 8 (44%) n.s.
Clinical Response to Treatment
All 48 patients responded to treatment, 38 of them (79%)
achieving a complete response (CR).
The achievement of CR was more frequently observed in cases
with low/intermediate than in those with high FLIPI-2 score (87
vs. 20%; p= 0.004).
No other clinical features impacted on response rate or on the
quality of response.
In particular, the presence of the molecular marker at baseline
did not correlate with the subsequent quality of response to
treatment: indeed, the CR rate was 45% in the subgroup of cases
with BCL2/JH detectable at baseline vs. 55% in the PCR-negative
cohort (p= 0.49).
Also the molecular tumor burden (according to the median
value or the 1 or 4th quartile) did not impact on the response
rate.
Overall and Progression-Free Survival
In the whole series, the 2-years PFS was 85% (Figure 1); it
was significantly longer for patients in CR than for those
in partial remission (PR) (91 vs. 57%; p = 0.002) and for
cases with low vs. those with high FLIPI-2 score (88 vs. 60%;
p= 0.004).
On the contrary, PFS did not differ between patients with
or without the molecular marker at baseline when BCL2/JH
rearrangement was assessed by qualitative PCR (2-years PFS,
83% for patients BCL2/JH-positive vs. 91% for those BCL2/JH-
negative; p= 0.25).
FIGURE 1 | Kaplan-Meier analysis of progression-free survival of the whole
cohort.
FIGURE 2 | Correlation between molecular tumor burden at baseline and
relapse rate: higher initial molecular burden was significantly correlated with a
higher probability of relapse/progression (mean of BCL2/JH copies in the
relapse-free subgroup: 9,411.8 ± 17,489.5 vs. 133,333.1 ± 230,940.1 in the
relapsed cases; p = 0.022).
At the contrary, a higher initial molecular burden
was significantly correlated with a higher probability of
relapse/progression (mean of BCL2/JH copies in the relapse-free
subgroup: 9,411.8 ± 17,489.5 vs. 133,333.1 ± 230,940.1 in the
relapsed cases; p= 0.022; Figure 2).
Nevertheless, when we stratified patients according to the
median number of BCL2/JH copies (0.014) or according to
quartiles (75 or 25th percentile), no differences in terms of PFS
were observed (2-years PFS, 100% for cases with BCL2/JH ratio
< 0.014 vs. 81% of cases with higher molecular tumor burden;
p= 0.08).
When the PCR status at baseline, quality of response (CR vs.
PR) and FLIPI-2 score (high/intermediate vs. low) were inserted
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as covariates in the multivariate analysis, all parameters lost their
statistical significance.
The 2-years OS for the whole series was 93.6% (Figure 3); the
only parameter that significantly impacted on survival was the
FLIPI-2 score, with 2-years OS of 97% for cases with low FLIPI-2
vs. 60% for those with high risk score (p= 0.001).
Differently from the PFS, the quality of response was not
prognostic in terms of OS (2-years OS 57% for patients in CR
vs. 37% for those in PR; p= 0.55).
Concerning the value of the presence of the molecular marker
or its load at baseline, the PCR status before treatment did not
significantly impact on OS.
The Impact of Treatment on MRD
After induction, all initially PCR-positive patients were re-
assessed by both qualitative and quantitative PCR: the qualitative
analysis became negative in all cases except two (93.3%); also in
the two patients with the mcr breakpoint, the molecular marker
disappeared.
In addition, QT-PCR showed the achievement of a very deep
response in themajority of cases: 25 patients (92.6%) achieved the
MRD negativity (≤1 × 10−6 copies), and 2 resulted positive but
not quantifiable (molecular tumor burden between 1× 10−5 and
1× 10−6). Overall, the median reduction of BCL2/JH burden was
4 logs, with 6 cases showing a reduction around or higher than
5 logs.
No significant differences in term of probability of relapse or
death nor in terms of PFS and OS length were observed in cases
with quantitative reductions higher or lower than the median of
4 logs.
DISCUSSION
Notwithstanding its long history, the MRD evaluation in FL and
its significance in the clinical practice are still matter of debate.
The recent European guidelines affirm that MRD has really got
a predictive and prognostic significance, but that it is not still
suitable for driving treatment of FL patients (Dreyling et al.,
2017).
FIGURE 3 | Kaplan-Meier analysis of overall survival of the whole cohort.
This is probably due to several considerations: (1) different
studies proved that MRD-negative patients show a better
prognosis, either when receiving chemo-immunotherapy or
high-dose treatment. Nevertheless, these experiences have been
conducted or in the context of large phase-III multicenter
trials or, at the opposite, on small series of patients, and thus
many physicians consider those results not fully exportable to
their routine activity; (2) notwithstanding the standardization
performed by some cooperative groups (van der Velden et al.,
2003; Pott et al., 2013), the availability of a common, easily
performable and cheap molecular method for investigatingMRD
is still lacking; (3) about MRD and R-bendamustine, few data are
still available, and thus further information on this specific setting
would be waited.
Our study is retrospective and involved a small number
of patients, but it represents the picture of that occurs to FL
patients in the real life. That statement is well supported by
the observation that our clinical results are superimposable to
those from other larger and pivotal trials: in particular, in our
series CR rate resulted 79%, 2-years PFS 85%, and 2-years OS
94%. These values result comparable to those recently reported
by Mondello et al. in 192 cases randomized to receive R-
bendamustine or R-CHOP (Mondello et al., 2016). Those authors
reported the superiority of R-bendamustine, with a significant
prolongation of the median PFS (152 vs. 132 months); in that
study, bendamustine offered 94% of ORR, and 63% of CR.
Probably, the higher rate of overall response (100%) found
in our series could be explained by the retrospective nature
of this study (where enrolment was only based on the DNA
availability).
Nevertheless, even with the limitation of the number of our
cases, the present study could add some information about MRD
in the setting of R-bendamustine to those previously reported by
Zohren and colleagues in the contex of the StiL trial (Rummel
et al., 2013).
Moreover, it is relevant to observe that our molecular data are
perfectly in line with those previously reported by other authors:
the BCL2/JH rearrangement at baseline has been detected in
62% of our patients; this is the same percentage reported in the
Gadolin trial (Pott et al., 2015) and in the StiL study (Zohren
et al., 2015), and slightly higher than that ourselves reported
in previous FIL trials (52% and 51%) (Ladetto et al., 2013;
Galimberti et al., 2014).
Also the number of cases with BM involvement documented
by microscopic observation but without molecular marker at
baseline was analogous to that previously reported (14% in the
present study vs. 17% in the FOLL05 trial) (Galimberti et al.,
2014): this phenomenon could be surely related to a possible
poor BM sampling, but also to the emerging demonstration that
at least 8–10% of the “PCR-negative” cases present some “rare”
breakpoints in the BCL2 gene (these rearrangements have not be
evaluated in the present study).
Thus, our study would suggest that R-bendamustine exerts a
so frequent and deep clearance of MRD that it would be able
to by-pass the negative prognostic impact usually played by the
MRD in other contexts, such as when R-CHOP, R-CVP, R-FM, or
R-FND were adopted as induction regimens.
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Indeed, in the present work the baseline molecular tumor
burden did not condition the quality of response, opposite to that
we observed in the FOLL05 study, where CR was achieved by the
half of the initially PCR-positive in respect of the PCR-negative
cases (Galimberti et al., 2014).
In the present study, relapsed patients presented an initial
molecular burden 15 times higher than that measured in not
relapsed/progressed cases, but this difference did not translate in
a significant advantage in terms of PFS. This could be probably
due to the small number of patients, but we cannot exclude that
it could be also the consequence of the more rapid and deeper
MRD clearance exerted by bendamustine: in our series, more
than 90% of cases achieved the MRD negativity, and quantitative
data showed that the majority of cases achieved a very deep
reduction of the molecular disease. The median reduction of 4
logs is encouraging in respect of the 2 logs reported after R-
CHOP (Galimberti et al., 2014) and the 2.5 logs reported after
yttrium-ibritumomab tiuxetan treatment (Ibatici et al., 2014).
Interestingly, the rapidity of the molecular clearance offered
by bendamustine has been already well demonstrated in the
Gallium (Pott et al., 2016) and Gadolin (Pott et al., 2015) trials,
where bendamustine was combined with obinutuzumab: in both
trials, the rapid efficacy of the R-bendamustine also in molecular
terms has been clearly demonstrated. It is also relevant that
in the arm with R-bendamustine of the Gallium trial, 90% of
patients became MRD-negative, a percentage comparable to that
observed in our study (93%) and that in that trial, as in the present
study, the MRD status did not condition the PFS length.
In conclusion, our study suggests that the combination of
rituximab and bendamustine, by exerting a rapid and deep
clearance of the molecular disease, could represent a highly
effective therapeutic approach to FL, also in terms of molecular
disease. The larger ongoing studies will show if the MRD would
be used as adjunctive tool for better selecting the more effective
treatment for FL patients.
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